NO20002972D0 - N-benzyl-3-indenylacetamidderivater for behandling av neoplasi - Google Patents

N-benzyl-3-indenylacetamidderivater for behandling av neoplasi

Info

Publication number
NO20002972D0
NO20002972D0 NO20002972A NO20002972A NO20002972D0 NO 20002972 D0 NO20002972 D0 NO 20002972D0 NO 20002972 A NO20002972 A NO 20002972A NO 20002972 A NO20002972 A NO 20002972A NO 20002972 D0 NO20002972 D0 NO 20002972D0
Authority
NO
Norway
Prior art keywords
benzyl
treatment
neoplasia
acetamide derivatives
indenyl
Prior art date
Application number
NO20002972A
Other languages
English (en)
Other versions
NO20002972L (no
NO317097B1 (no
Inventor
Gerhard Sperl
Paul Gross
Klaus Brendel
Gary A Piazza
Rifat Pamukcu
Original Assignee
Cell Pathways Inc
Univ Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/989,353 external-priority patent/US5948779A/en
Application filed by Cell Pathways Inc, Univ Arizona filed Critical Cell Pathways Inc
Publication of NO20002972D0 publication Critical patent/NO20002972D0/no
Publication of NO20002972L publication Critical patent/NO20002972L/no
Publication of NO317097B1 publication Critical patent/NO317097B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20002972A 1997-12-12 2000-06-09 N-benzyl-3-indenylacetamidderivater for behandling av neoplasi NO317097B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/989,353 US5948779A (en) 1997-12-12 1997-12-12 Substituted condensation products of n-benzyl-3-indenyl acetamides with heterocyclic aldehydes
US09/206,245 US6066634A (en) 1997-12-12 1998-12-07 Substituted condensation products of N-benzyl-3-indenylacetamides heterocyclic aldehydes for neoplasia
PCT/GB1998/003712 WO1999031065A1 (en) 1997-12-12 1998-12-11 N-benzyl-3-indenylacetamides derivatives for treating neoplasia

Publications (3)

Publication Number Publication Date
NO20002972D0 true NO20002972D0 (no) 2000-06-09
NO20002972L NO20002972L (no) 2000-08-09
NO317097B1 NO317097B1 (no) 2004-08-09

Family

ID=26901185

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002972A NO317097B1 (no) 1997-12-12 2000-06-09 N-benzyl-3-indenylacetamidderivater for behandling av neoplasi

Country Status (18)

Country Link
US (3) US6166053A (no)
EP (1) EP1044187B1 (no)
JP (1) JP4307719B2 (no)
CN (1) CN100436418C (no)
AT (1) ATE257152T1 (no)
AU (1) AU752072B2 (no)
BR (1) BR9813540A (no)
CA (1) CA2314339C (no)
CZ (1) CZ298826B6 (no)
DE (1) DE69820908T2 (no)
ES (1) ES2212383T3 (no)
HU (1) HU227153B1 (no)
IL (1) IL136603A0 (no)
NO (1) NO317097B1 (no)
NZ (1) NZ504958A (no)
PL (1) PL196936B1 (no)
TR (1) TR200001687T2 (no)
WO (1) WO1999031065A1 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2314339C (en) * 1997-12-12 2009-09-08 Cell Pathways, Inc. N-benzyl-3-indenylacetamide derivatives for treating neoplasia
IL132366A0 (en) * 1998-10-15 2001-03-19 Cell Pathways Inc Methods for identifying compounds for inhibition of neoplastic lesions and pharmaceutical compositions containing such compounds
CA2407031A1 (en) 2000-04-19 2001-10-25 Lilly Icos Llc Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
DE10058663A1 (de) * 2000-11-25 2002-05-29 Merck Patent Gmbh Verwendung von Thienopyrimidinen
WO2002067936A1 (en) * 2001-02-21 2002-09-06 Cell Pathways, Inc. Methods for treatment of inflammatory bowel disease
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
US20030073711A1 (en) * 2001-08-23 2003-04-17 Whitehead Clark M. Methods for treatment of scleroderma
US20030073740A1 (en) * 2001-08-23 2003-04-17 Whitehead Clark M. Methods for treatment of lupus erythematosus
US6479493B1 (en) * 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
CN100398522C (zh) * 2003-08-20 2008-07-02 Irm责任有限公司 组织蛋白酶s的抑制剂
US6995622B2 (en) * 2004-01-09 2006-02-07 Robert Bosh Gmbh Frequency and/or phase compensated microelectromechanical oscillator
WO2005120279A2 (en) 2004-06-02 2005-12-22 Merit Diamond Corporation Comfort interior for jewelry and jewelry including that interior
CN1332930C (zh) * 2005-08-05 2007-08-22 中国科学院上海有机化学研究所 制备乙氰菊酯前体的方法
CN101365461B (zh) * 2006-01-04 2013-07-24 南方研究所 舒林酸衍生物、其用途和其制备
WO2009022756A1 (ja) * 2007-08-13 2009-02-19 Katayama Chemical Industries Co., Ltd. 虚血性疾患の診断及び治療
WO2010053910A1 (en) * 2008-11-04 2010-05-14 Wellstat Therapeutics Corporation Synthesis of (phenylalkyloxy)phenyl-oxobutanoic acids
IN2012DN01935A (no) 2009-08-07 2015-08-21 Auckland Uniservices Ltd
US9862698B2 (en) 2014-12-16 2018-01-09 Adt Pharmaceuticals, Inc. Indenyl compounds, pharmaceutical compositions, and medical uses thereof
US20160168108A1 (en) 2014-12-16 2016-06-16 Adt Pharmaceuticals, Inc. Method of treating or preventing ras-mediated diseases
CN112020354A (zh) 2018-04-26 2020-12-01 Adt制药有限责任公司 抗癌茚类、茚满类、氮杂茚类、氮杂茚满类、药物组合物和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650720B2 (en) * 1991-03-08 1994-06-30 Fgn, Inc. Method for treating patients with precancerous lesions by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof
US6063818A (en) * 1996-06-13 2000-05-16 Cell Pathways Inc. Substituted benzylidene indenyl formamides, acetamides and propionamides
US5948779A (en) * 1997-12-12 1999-09-07 Cell Pathways, Inc. Substituted condensation products of n-benzyl-3-indenyl acetamides with heterocyclic aldehydes
CA2314339C (en) * 1997-12-12 2009-09-08 Cell Pathways, Inc. N-benzyl-3-indenylacetamide derivatives for treating neoplasia

Also Published As

Publication number Publication date
ES2212383T3 (es) 2004-07-16
US6610854B2 (en) 2003-08-26
CZ298826B6 (cs) 2008-02-20
CA2314339C (en) 2009-09-08
PL196936B1 (pl) 2008-02-29
EP1044187B1 (en) 2004-01-02
CN1281436A (zh) 2001-01-24
NO20002972L (no) 2000-08-09
HUP0100170A1 (hu) 2001-07-30
CN100436418C (zh) 2008-11-26
TR200001687T2 (tr) 2000-10-23
US6426349B1 (en) 2002-07-30
DE69820908T2 (de) 2004-12-23
CA2314339A1 (en) 1999-06-24
NZ504958A (en) 2003-03-28
BR9813540A (pt) 2000-10-10
AU1498199A (en) 1999-07-05
AU752072B2 (en) 2002-09-05
JP4307719B2 (ja) 2009-08-05
EP1044187A1 (en) 2000-10-18
DE69820908D1 (de) 2004-02-05
NO317097B1 (no) 2004-08-09
CZ20002157A3 (cs) 2000-10-11
ATE257152T1 (de) 2004-01-15
HUP0100170A3 (en) 2001-12-28
HU227153B1 (en) 2010-08-30
US6166053A (en) 2000-12-26
IL136603A0 (en) 2001-06-14
JP2002508358A (ja) 2002-03-19
PL341151A1 (en) 2001-03-26
WO1999031065A1 (en) 1999-06-24
US20030009033A1 (en) 2003-01-09

Similar Documents

Publication Publication Date Title
NO20002972L (no) N-benzyl-3-indenylacetamidderivater for behandling av neoplasi
CA2387873A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
CY1115521T1 (el) Σχηματισμοi οι οποiοι περιλαμβανουν αντι-κωδικευσης νουκλεοτιδια σε συνδετινες
FI932032A0 (fi) Kinazolinderivat foer oekande av antitumoeraktivitet
ATE109002T1 (de) Wasserlösliche antineoplastische taxolderivate.
ZA200201494B (en) Benzodiazepin derivatives, the production and use thereof.
AR023777A1 (es) Nuevos compuestos
ES2167401T3 (es) Uso de ascorbil-gamma-linolenato o un ascorbil-dihomo-gamma-linolenato para el tratamiento de asma, cancer, enfermedades cardiovasculares y anti-inflamatorias.
DE69921981D1 (de) ZUSAMMENSETZUNG AUS MUTIERTERN PEPTIDEN, DERIVATE DES hsp70 UND IHRE VERWENDUNG IN DER IMMUNTHERAPIE VON KREBS
EE03858B1 (et) Konjugaadid, nende kasutamine eesnäärmevähi ravimites, farmatseutiline kompositsioon ja selle valmistamine
TR200402628T4 (tr) Androjenetik ve yaygın alopezinin tedavisinde melatonin maddesinin kullanımı
NL7612030A (nl) Nieuwe dipeptide-derivaten en hun zouten, en hun toepassing bij de bepaling van enzym-activiteiten.
EP0910380A4 (en) SUBSTITUTED BENZYLIDE INDENYL FORMAMID, ACETAMIDE AND PROPIONAMIDE
DK1025100T3 (da) 3-substituerede tetrahydropyridopyrimidinonderivater, fremstilling og anvendelsen heraf
EE9900218A (et) 1,4-diasabitsüklo[2.2.2]okt-2-üülmetüülbensoaadi derivaadid, nende valmistamine ja kasutamine raviks
DE60026046D1 (de) 5-hydroxysapogenin derivate mit aktivität gegen demenz
DE19982139D2 (de) Rehabilitations-Gerät
EE9700177A (et) Parendatud omadustega aprotiniini derivaadid, nende kasutamine ravimite tootmiseks ja aprotiniini derivaate sisaldavad ravimid
ZA982136B (en) Novel carboxylic acid derivatives, their preparation and use in treating cancer.
CA2298820A1 (en) The use of 1,3,4,6-tetrahydroxy-helianthrone and its derivatives in photodynamic therapy and certain such novel derivatives
ZA978772B (en) N-(2-benzothiazolyl)-1-piperidineethanamine derivatives, their preparation and their use in therapy.
IT1298376B1 (it) Trattamento di reticolazione e sterilizzazione per la produzione di manufatti in polietilene ad elevate caratteristiche tribologiche,
ATE417926T1 (de) Zusammensetzungen zur modulierung der länge von telomeren
ES517287A0 (es) Procedimiento y disposicion para el tratamiento termico, en particular para el secado, de bandas de genero en movimiento.
DK1237537T3 (da) Præparat i form af en gel til modtagelse af et aktivt stof i oplösning eller suspension, især til anvendelse på en slimhinde, og fremgangsmåde til dets fremstilling

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees